The Danish biotechnology research company, Zealand Pharma A/S has appointed Steven Johnson as Chief Development Officer. Steven will join the executive team to lead regulatory and development strategies.

His appointment, alongside Chief Medical Officer, David Kendall and recently appointed Chief Scientific Officer, Utpal Singh, will strengthen the company’s strategy to lead the field in innovation in the management of obesity and other related conditions.

He brings with him nearly 30 years of experience driving drug development and regulatory strategy across the pharmaceutical industry. Johnson joins Zealand Pharma from UCB Biopharma, where he most recently served as Senior Vice President and Head of Regulatory Stakeholders, responsible for leading late phase clinical development, global regulatory affairs, biometrics and operational excellence. During Johnson’s tenure at UCB, his teams secured global approvals for key therapies across multiple therapeutic areas. Previously, he held senior leadership roles at Medpace, Inc. and Novo Nordisk.

Johnson began his career at the US Food and Drug Administration, where he served as a Master Reviewer in the Division of Metabolic and Endocrine Drug Products.